Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% Icodextrin

Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for...

Full description

Saved in:
Bibliographic Details
Published in:Drug delivery Vol. 8; no. 1; pp. 9 - 12
Main Authors: Hosie, K, Gilbert, J A, Kerr, D, Brown, C B, Peers, E M
Format: Journal Article
Language:English
Published: England Informa UK Ltd 2001
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for intraperitoneal (IP) drug delivery have short residence times, however, which can limit the exposure of all areas of the peritoneum to the active agent. Icodextrin 4% solution was compared with saline and a glucose-based peritoneal dialysis solution in a clinical study of IP residence time. The study was carried out during the fortnightly rest phase in 9 patients undergoing 5-fluorouracil (5-Fu) IP treatment for colorectal cancer. The volume remaining in the peritoneal cavity was measured at 0, 12, 24, 48, 72, and 96 hr after an instillation of 2 liters of each fluid. Saline (n = 3 dwells) and glucose (n = 3 dwells) peritoneal dialysis solutions were almost fully absorbed by 24 hr, and the patients experienced discomfort when using these solutions. In contrast, icodextrin 4% solution (n = 188 dwells) maintained its instilled volume for up to 48 hr, and half the instilled volume remained after 72 and 96 hr. This result would allow extensive and prolonged coverage of the peritoneal surface. Icodextrin 4% solution may be an effective vehicle to deliver therapeutic agents into the peritoneal cavity.
AbstractList Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have demonstrated, not only a regional advantage in concentration of the active agent, but also improved long-term outcomes. Solutions currently used for intraperitoneal (IP) drug delivery have short residence times, however, which can limit the exposure of all areas of the peritoneum to the active agent. Icodextrin 4% solution was compared with saline and a glucose-based peritoneal dialysis solution in a clinical study of IP residence time. The study was carried out during the fortnightly rest phase in 9 patients undergoing 5-fluorouracil (5-Fu) IP treatment for colorectal cancer. The volume remaining in the peritoneal cavity was measured at 0, 12, 24, 48, 72, and 96 hr after an instillation of 2 liters of each fluid. Saline (n = 3 dwells) and glucose (n = 3 dwells) peritoneal dialysis solutions were almost fully absorbed by 24 hr, and the patients experienced discomfort when using these solutions. In contrast, icodextrin 4% solution (n = 188 dwells) maintained its instilled volume for up to 48 hr, and half the instilled volume remained after 72 and 96 hr. This result would allow extensive and prolonged coverage of the peritoneal surface. Icodextrin 4% solution may be an effective vehicle to deliver therapeutic agents into the peritoneal cavity.
Author K. Hosie, J. A. Gilbert, D. Kerr, C. B. Brown, E. M. Peers
Author_xml – sequence: 1
  givenname: K
  surname: Hosie
  fullname: Hosie, K
  organization: Northern General Hospital, Sheffield, United Kingdom
– sequence: 2
  givenname: J A
  surname: Gilbert
  fullname: Gilbert, J A
– sequence: 3
  givenname: D
  surname: Kerr
  fullname: Kerr, D
– sequence: 4
  givenname: C B
  surname: Brown
  fullname: Brown, C B
– sequence: 5
  givenname: E M
  surname: Peers
  fullname: Peers, E M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11280443$$D View this record in MEDLINE/PubMed
BookMark eNplkMtOwzAQRS1URB_wAyyQNywDfsV2EBvUUqhUhBCwjhw_qKvEqZwE0b_HqLBiFjObo5k5dwpGoQ0WgHOMrjCS6BojgUXOEKYoFeEFOwITTDnP8oLIEZggxIpMkpyNwbTrtgnimJATMMaYSMQYnYCXZT14Axf7oBqvO-gDfFIBtg6mvgp9VDsbfZ8Oqxou4vABF7b2nzbu4WtbD71vww1kl3ClW2O_-ujDKTh2qu7s2e-cgffl_dv8MVs_P6zmd-tM50z0GdPEIMa1MJUVFDOhOKJKKOEKpSmpmNNcElZwVMkqJ3mOuHHJRyplHOeYzsDFYe9uqBpryl30jYr78s8tAbcHwAfXxkZtkkK_0SractsOMaTnSozKnyjL_1HSb40WZJk
CitedBy_id crossref_primary_10_1007_s00404_010_1423_3
crossref_primary_10_1016_S1525_0016_03_00057_1
crossref_primary_10_1016_j_fertnstert_2016_08_012
crossref_primary_10_1016_j_gmit_2014_01_004
crossref_primary_10_5301_je_5000190
crossref_primary_10_1016_j_rigapp_2006_02_001
crossref_primary_10_1002_14651858_CD011254_pub2
crossref_primary_10_1016_j_ygyno_2006_06_005
crossref_primary_10_3390_jcm11061476
crossref_primary_10_1111_j_1463_1318_2009_02132_x
crossref_primary_10_1007_s00464_013_3102_5
crossref_primary_10_1016_S0090_8258_02_00148_8
crossref_primary_10_1308_003588406X114730
crossref_primary_10_1111_j_1463_1318_2007_01357_x
crossref_primary_10_1016_j_actbio_2017_08_002
crossref_primary_10_1016_j_fertnstert_2006_12_084
crossref_primary_10_1089_gyn_2010_0084
crossref_primary_10_1016_S1055_3207_03_00039_5
crossref_primary_10_1002_jbm_a_33083
crossref_primary_10_1002_mabi_202000395
crossref_primary_10_1016_j_rigp_2005_04_003
crossref_primary_10_17116_hirurgia2020091116
crossref_primary_10_1016_S0140_6736_13_61687_6
crossref_primary_10_1016_j_jconrel_2018_11_010
crossref_primary_10_1053_ejso_2002_1348
crossref_primary_10_1002_jbm_b_33824
crossref_primary_10_1007_s11605_011_1819_9
crossref_primary_10_1016_j_jss_2018_10_003
crossref_primary_10_1089_gyn_2014_0052
crossref_primary_10_1007_s10397_007_0333_2
crossref_primary_10_3390_medicina58030386
crossref_primary_10_1097_GCO_0b013e3283073a6c
crossref_primary_10_2217_fon_09_11
crossref_primary_10_1046_j_1463_1318_2003_00447_x
crossref_primary_10_1152_ajprenal_00313_2004
crossref_primary_10_1016_j_actbio_2020_08_036
crossref_primary_10_1158_0008_5472_CAN_05_2691
crossref_primary_10_1002_14651858_CD001298_pub4
crossref_primary_10_1002_14651858_CD001298_pub5
crossref_primary_10_1016_j_ejogrb_2009_12_026
crossref_primary_10_1016_j_pog_2010_07_004
crossref_primary_10_1016_j_ijsu_2013_07_019
crossref_primary_10_1186_1471_2482_13_34
crossref_primary_10_1016_j_progpolymsci_2014_10_004
crossref_primary_10_1097_MS9_0000000000001810
crossref_primary_10_1016_j_ejso_2007_05_007
crossref_primary_10_1111_j_1463_1318_2009_02007_x
crossref_primary_10_1155_2013_720858
crossref_primary_10_1016_j_ijsu_2007_05_010
crossref_primary_10_1016_j_suronc_2014_03_004
crossref_primary_10_3748_wjg_14_2179
crossref_primary_10_1016_j_ejpb_2007_03_027
crossref_primary_10_1515_pp_2017_0002
crossref_primary_10_1016_j_fertnstert_2006_05_023
crossref_primary_10_1590_S0101_98802006000200014
crossref_primary_10_1016_j_canlet_2008_07_024
crossref_primary_10_1093_humupd_dml061
crossref_primary_10_1016_S0022_4804_03_00162_8
ContentType Journal Article
Copyright 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001
Copyright_xml – notice: 2001 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2001
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1080/107175401300002694
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1366-5928
EndPage 12
ExternalDocumentID 11280443
10_1080_107175401300002694
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.GJ
00X
03L
0BK
0R~
123
29R
36B
4.4
53G
5RE
5VS
AACCU
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABCRQ
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ACENM
ACFUF
ACGEJ
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
ADXPE
AECIN
AEGXH
AENEX
AEOZL
AEYQI
AFAUU
AFKVX
AFQCT
AFWLO
AGAFX
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJEBJ
AJWEG
AJXHO
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AWYRJ
BABNJ
BLEHA
BOHLJ
BVLLS
CAG
CCCUG
COF
CS3
DEIEU
DKSSO
DLVIE
DTRLO
DU5
DZHFC
EAP
EBC
EBD
EBS
EBX
EDH
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
J.N
JFOCU
KRBQP
KWAYT
KYCEM
L7B
LJTGL
M44
M4Z
MK0
O9-
OVD
QRXOQ
RNANH
RVRKI
SV3
TEORI
TFDNU
TFL
TFW
TUS
UHWXJ
V1S
ZGI
ZXP
~1N
~KM
0VX
0YH
29G
5GY
7X7
88I
8FI
8FJ
ABUWG
ADBBV
AFKRA
ALIPV
AOIJS
ARJSQ
AZQEC
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
DWQXO
ECM
EIF
FYUFA
GNUQQ
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
M2P
NPM
OK1
P2P
PIMPY
PQQKQ
PROAC
RPM
TDBHL
UKHRP
ID FETCH-LOGICAL-c547t-4c2d046c7dbe73147a603a7a7f9ac32b4fc6824960b8b525506df0498aadf6613
ISSN 0049-8254
1071-7544
IngestDate Sat Sep 28 08:38:41 EDT 2024
Tue Jul 04 19:21:03 EDT 2023
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c547t-4c2d046c7dbe73147a603a7a7f9ac32b4fc6824960b8b525506df0498aadf6613
OpenAccessLink https://www.tandfonline.com/doi/pdf/10.1080/107175401300002694?needAccess=true
PMID 11280443
PageCount 4
ParticipantIDs pubmed_primary_11280443
informahealthcare_journals_10_1080_107175401300002694
PublicationCentury 2000
PublicationDate 20010000
2001 Jan-Mar
PublicationDateYYYYMMDD 2001-01-01
PublicationDate_xml – year: 2001
  text: 20010000
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Drug delivery
PublicationTitleAlternate Drug Deliv
PublicationYear 2001
Publisher Informa UK Ltd
Publisher_xml – name: Informa UK Ltd
SSID ssj0006122
ssj0008125
Score 1.8878134
Snippet Interest in targeting drugs into the peritoneal cavity for intra-abdominal cancers or infections is undergoing a revival as recent clinical trials have...
SourceID pubmed
informahealthcare
SourceType Index Database
Publisher
StartPage 9
SubjectTerms Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - administration & dosage
Colorectal Neoplasms - drug therapy
Dialysis Solutions - administration & dosage
Drug Delivery Systems
Female
Fluorouracil - administration & dosage
Glucans - administration & dosage
Glucose - administration & dosage
Humans
Icodextrin
Kidney - drug effects
Kidney Function Tests
Male
Middle Aged
Peritoneal Dialysis
Water-Electrolyte Balance
Title Fluid Dynamics in Man of an Intraperitoneal Drug Delivery Solution: 4% Icodextrin
URI https://www.ncbi.nlm.nih.gov/pubmed/11280443
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Pb9MwFLZYdwAOaAwY48fkA9slS5TETuJwK23GoOpURCftViW2A5WmgtL2sP-e92InqRYhARJSFFVWZSV-X5_9ud_7TMg7DcxEBTJwZSBTICiSuUJE0uUFStfCMhE-ViNffk2ubsQ441m3mdO1_ddIQxvEGitn_yLabafQAJ8h5nCHqMP9j-J-cbtdKmdsDpqvxa7TvF4S5vX2HxZbVUt04MZ8V22_Qca5RW0G5BD7XLhJwE_DyPlU17tvKmvObZewN3qF1k2bHZHPxMPzR8w_HZ89Z-g5H5fonVUn-LHnTHRlyg095wNcDfPPPGfqOTNtRfjt5kO37dAUS11PduRHdYblqYus08wvJqmyOHaj1BaB26wreuAyGTTdmYqNwLqX5I0qMkAmGiE9xDkXC3K7Ka0VGgbWAbX_5T2yH0Ju4gOyPxxlV9N2-oYln7GYty9iK63QfrPfy2NyYA1uv7dyvXsEpV6ozA_IE8sw6NBA4yl5oFeH5OGoOdjvkJzNjF353Tmdd9V363N6RmedkfndM_KlxhJtsESXKwpYoj9KCvd7WKKIJdpgiTZYek_5Ke1w9JxcX2Tz0aVrj-BwZcSTjctlqHwey0QVOmEBT_LYZ3mSJ2WaSxYWvJSxAAYf-4UoIqCnfqxKGDmR56qEpR97QQYreIyXhBZpUapYqaBUEY8FFzrQYQHdsVBLlrNjEvWGcmF_WOvF7wN5TI7McC9-Gn8WILWh8Dlnr_6xx9fkkVEa4vWGDDbVVr8le2u1PbFgOQHaNZr-ArVyer8
link.rule.ids 315,782,786,4030,27934,27935,27936,61278,61459
linkProvider Taylor & Francis
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8JAEJ4oHNCDIr7wuQflRJO2u20XL4bwCEQgGDHxRtrdrpKQaigc-PfO0hYS8aRJ096mm93ZmfkmM98A3IWITKQlLENYooYARVCDc0cYLNCla7byuKm7kTsv3uCNN1uaJucx64XRZZUaQ6uEKGJlq_Xl1snorCQOvwhCHI0MtLnVvZi7kEc_46Ba5-uN1qC_NsbowBPCcFYzNBhK-2Z-l7IPxZSu9GNdfPUj3Fy5nfbhvxdchIM04iT1REWOYCeMSlBoZIPeSlAZJvTVyyoZbbqx4iqpkOGG2Hp5DM_t6WIiSTMZYh-TSUT6fkQ-FcF3V2eJNW2yZvfG_zVni3fSDKe67mNJsuzbA2H3pLvqo5_PJtEJvLZbo0bHSEcyGMJh3txgwpaIqIUng9CjFvN816S-53uq5gtqB0wJlyOic82ABw7CFdOVCvee-75UGArQU8hFuIxzIEEtUNKV0lLSYS5nPLRCO0Bx1A4F9WkZnK3DGKcXLB5bKbXp9s6W4Sw5sPFXwteBIMfmJmP04o8Sb6HQGfV741538HQJe0kVmn6uIDefLcJr2I3l4iZVvW96tNW5
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ba8IwFD5MhV0eNudu7pqHzScLbZM2cQ8DsRZlUxxzsDdpk2YTpBO1D_77JbZV2Pa0QWkhD6chl5PzhfN9B-A2UshEWNwyuMUbCqBwbDDmcIOEOnXNlpSZmo3ceaH9N-a1tUzOQ86F0WmVGkPLVChi5av15p4KmWfEqa_CII4GBtrbaipmAUrqpKasCKVmq93vrX2xak31wknD0Fgoo838bmUPypla6cc69-pbtLk6dfyD__a3DPtZvIma6QI5hK0orsBOKy_zVoHaIBWvXtbRcMPFmtdRDQ02stbLI3j2J8lYIC8tYT9H4xj1ghh9SqTeXX1HrEWTtba3-p83S96RF0101scS5Xdv94jcoe6KRb-YjeNjePXbw1bHyAoyGNwhdGEQbguFpzkVYUSxRWjgmjigAZWNgGM7JJK7TOE51wxZ6CiwYrpCqqFnQSCkCgTwCRRj1Y0zQGEjlMIVwpLCIS4jLLIiO1TmsB1xHOAqOD_mYpRtr_nIyoRNf45sFU7T-RpNU7UOBXFsZhKCz_9o8Qa2B54_eur2Hy9gN01B088lFBezJLqCwlwk19nC-wIN1dRo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fluid+Dynamics+in+Man+of+an+Intraperitoneal+Drug+Delivery+Solution%3A+4%25+Icodextrin&rft.jtitle=Xenobiotica&rft.au=K.+Hosie%2C+J.+A.+Gilbert%2C+D.+Kerr%2C+C.+B.+Brown%2C+E.+M.+Peers&rft.date=2001&rft.pub=Informa+UK+Ltd&rft.issn=0049-8254&rft.eissn=1366-5928&rft.volume=8&rft.issue=1&rft.spage=9&rft.epage=12&rft_id=info:doi/10.1080%2F107175401300002694&rft.externalDocID=10_1080_107175401300002694
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0049-8254&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0049-8254&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0049-8254&client=summon